2019
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care 2019, 42: 1147-1154. PMID: 30728224, PMCID: PMC6973545, DOI: 10.2337/dc18-2316.Peer-Reviewed Original ResearchConceptsType 1 diabetesSodium-glucose cotransporter inhibitorsDiabetic ketoacidosisCotransporter inhibitorsSGLT inhibitorsNear-normal blood glucose levelsOral antidiabetes medicationsBlood glucose levelsAntidiabetes medicationsInhibitor useBlood pressureAbsolute riskMild hyperglycemiaDKA riskGlycemic variabilityConsensus reportGlucose levelsBody weightDrug AdministrationDiabetesType 1U.S. FoodMedical communityKetoacidosisInternational consensus
2015
Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes
Mazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, Hershey T, Cato A, Aye T, Fox L, Wilson DM, Tansey MJ, Tamborlane W, Peng D, Raman M, Marzelli M, Reiss AL. Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes 2015, 65: 476-485. PMID: 26512024, PMCID: PMC4747456, DOI: 10.2337/db15-1242.Peer-Reviewed Original ResearchConceptsEarly-onset type 1 diabetesType 1 diabetesBlood glucose levelsWhite matter volumeGlucose levelsMatter volumeTime pointsBrain volumeAge-matched control subjectsCortical gray matter volumeMeasures of hyperglycemiaMean HbA1c levelCurrent treatment guidelinesManagement of diabetesRapid brain maturationGray matter volumeTime of scanCortical surface areaHbA1c levelsTreatment guidelinesControl subjectsGlycemic variationsLongitudinal time pointsBrain maturationDiabetes
2014
Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
Sherr JL, Collazo M, Cengiz E, Michaud C, Carria L, Steffen AT, Weyman K, Zgorski M, Tichy E, Tamborlane WV, Weinzimer SA. Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose. Diabetes Care 2014, 37: 773-779. PMID: 24170766, PMCID: PMC3931387, DOI: 10.2337/dc13-1608.Peer-Reviewed Original ResearchConceptsBlood β-hydroxybutyrate levelsΒ-hydroxybutyrate levelsBasal insulinBlood glucose levelsBasal insulin infusionGlucose levelsBlood glucoseInsulin infusionMorning blood glucose levelsType 1 diabetic subjectsUsual basal ratesBasal rateLow glucose levelsSignificant ketonemiaDiabetic ketoacidosisDiabetic subjectsControl nightSensor-augmented pump systemGlucose valuesType 1Experimental nightInsulinLow glucoseNext morningInfusion
2013
Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes
Sherr JL, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA. Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. Diabetes Care 2013, 36: 2909-2914. PMID: 23757427, PMCID: PMC3781513, DOI: 10.2337/dc13-0010.Peer-Reviewed Original ResearchConceptsNocturnal hypoglycemiaType 1 diabetesAfternoon exerciseInsulin deliveryAntecedent exerciseTarget blood glucose rangeCL insulin deliveryClosed-loop insulin deliveryLoop insulin deliveryTarget rangeBlood glucose levelsBlood glucose rangeMaximum heart rateCL controlBrisk treadmillReduced hypoglycemiaSedentary dayExercise dayPercentage of timeGlucose levelsHeart rateGlucose valuesType 1Random orderStudy period
2006
Effects of hypoglycemia on human brain activation measured with fMRI
Anderson AW, Heptulla RA, Driesen N, Flanagan D, Goldberg PA, Jones TW, Rife F, Sarofin H, Tamborlane W, Sherwin R, Gore JC. Effects of hypoglycemia on human brain activation measured with fMRI. Magnetic Resonance Imaging 2006, 24: 693-697. PMID: 16824963, DOI: 10.1016/j.mri.2006.03.013.Peer-Reviewed Original ResearchConceptsFunctional magnetic resonance imagingBrain activationHuman brain activationPassive sensory stimulationCognitive tasksFMRI activityVisual stimuliEuglycemic clamp studiesBlood glucose levelsLevel-dependent contrastEffects of hypoglycemiaBOLD signalSensory stimulationHealthy human subjectsVisual stimulationMagnetic resonance imagingHyperinsulinemic hypoglycemicHealthy brainAcute hypoglycemiaGlucose levelsClamp studiesResonance imagingFractional signal changeHypoglycemiaEuglycemia
2005
Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes Mellitus
Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ. Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes Mellitus. The Journal Of Pediatrics 2005, 147: 528-534. PMID: 16227041, PMCID: PMC2258153, DOI: 10.1016/j.jpeds.2005.04.065.Peer-Reviewed Original ResearchConceptsGlucose levelsExercise nightsOvernight hypoglycemiaType 1 diabetes mellitusOvernight glycemic controlClinical Research CenterRisk of hypoglycemiaEffects of exerciseImpact of exerciseBlood glucose levelsAfternoon exerciseDiabetes mellitusGlycemic controlInsulin dosesSedentary dayExercise dayExercise sessionsDiabetes managementHypoglycemiaSeparate daysClinical sitesType 1Central laboratoryMellitusT1DM
2003
Insulin Pump Therapy in Childhood Diabetes Mellitus
Tamborlane WV, Fredrickson LP, Ahern JH. Insulin Pump Therapy in Childhood Diabetes Mellitus. Treatments In Endocrinology 2003, 2: 11-21. PMID: 15871551, DOI: 10.2165/00024677-200302010-00002.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionSevere hypoglycemiaEffectiveness of CSIIType 1 diabetes mellitusRapid-acting insulin analoguesDevelopment of ketoacidosisNear-normal glycemiaOvernight glycemic controlProgrammable basal ratesExcessive weight gainSelection of patientsExercise-induced hypoglycemiaInitiation of treatmentInsulin pump therapySubcutaneous insulin infusionBlood glucose levelsTiming of mealsQuality of lifeContinuous glucose monitoringCare of childrenBolus capabilitiesPediatrie patientsDiabetic ketoacidosisVascular complicationsDiabetes mellitus
1985
Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes.
Simonson DC, Tamborlane WV, DeFronzo RA, Sherwin RS. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Annals Of Internal Medicine 1985, 103: 184-90. PMID: 3893253, DOI: 10.7326/0003-4819-103-2-184.Peer-Reviewed Original ResearchConceptsCounterregulatory hormone responsesPump treatmentHormone responseCounterregulatory hormone releaseInsulin pump treatmentPerception of hypoglycemiaIntensive insulin therapyIntensive insulin treatmentInsulin clamp techniqueType IBlood glucose levelsCounterregulatory hormonesGlucose counterregulationInsulin therapyHypoglycemic stimulusHypoglycemic episodesGlucagon releaseHealthy controlsInsulin treatmentHormone releaseStudy groupGlucose levelsHypoglycemic periodNormal controlsHypoglycemia